Foghorn Therapeutics (FHTX) Interest & Investment Income (2022 - 2026)

Foghorn Therapeutics' Interest & Investment Income history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 35.29% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $7.8 million, a 35.86% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, down 26.51% from the prior year.
• Interest & Investment Income grew to $1.7 million in Q1 2026 per FHTX's latest filing, from $1.7 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $3.5 million in Q3 2024 and bottomed at $235000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $2.4 million (2024), against an average of $2.3 million.
• Across the five-year window, Interest & Investment Income jumped 1035.74% in 2023 and plunged 44.7% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $2.4 million in 2022, then climbed by 11.95% to $2.7 million in 2023, then advanced by 16.39% to $3.1 million in 2024, then plunged by 44.7% to $1.7 million in 2025, then advanced by 1.75% to $1.7 million in 2026.
• Per Business Quant, the three latest FHTX Interest & Investment Income figures stand at $1.7 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025).